IRCT20220529055013N1 IRCT 2022-06-23 Public Sector medical University Dapagliflozin in Acute Heart failure AHF( Acute Heart Failure) Efficacy of Dapagliflozin in diabetic and nondiabetic patients with Acute heart failure 2022-07-01 anticipated 160 Complete https://irct.ir/trial/64243 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The participants will be divided into groups as control and study groups. the study drug( dapagliflozin) will be prescribed as add on therapy to the conventional treatment of acute heart failure in a 1:1. simple randomization in 1:1 among the individuals taking participation in the study, Blinding description: The study participants will be blinded. 4 Heart failure with reduced ejection fraction. Intervention 1: Intervention group: Tab Dapagliflozin 10 mg orally as add on therapy to the conventional treatment will be prescribed to the study participants. Intervention 2: Control group: The participants in this group will be prescribed with the conventional treatment for heart failure. Yes - There is a plan to make this available What will be shared: title: Results. Tables and graphs of primary outcome and secondary outcome will be shared. When: it will be given in the duration of 10 months to 36 months after publishing. It will be available lifelong To whom: everyone Conditions: everyone who want to take advantage of this trial results will be allowed for the service of humanity. Where to obtain: They can talk to principal investigator of this trial Syedah Fauzia Fatima Gilani. E-mail: fauziagilani@gmail.com How to obtain: Email Comments: